Following a limited submission
AWMSG advice |
|
| Status: Recommended | |
Adrenaline (EURneffy®) is recommended as an option for use in NHS Wales for the emergency treatment of severe allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise-induced anaphylaxis. Treatment is indicated for adults and children with a body weight ≥ 30kg. Prescribers are reminded to consult the British Society for Allergy and Clinical Immunology (BSACI) advice on the prescribing of self-administered emergency adrenaline to people at risk of anaphylaxis. |
|
Medicine details |
|
| Medicine name | Intranasal adrenaline (EURneffy) |
| Formulation | 2 mg in 100 microlitres nasal spray, solution in single-dose container |
| Reference number | 6284 |
| Indication | For the emergency treatment of allergic reactions (anaphylaxis), and idiopathic or exercise induced anaphylaxis, in adults and children weighing 30kg or more |
| Company | ALK Abello |
| BNF chapter | Respiratory system |
| Assessment type | Limited |
| Status | Recommended |
| Scrutiny Panel meeting date | 05/03/2026 |
| LOWMAG meeting date | 01/07/2026 |
| AWMSG meeting date | 09/09/2026 |
| Date of issue | 15/09/2026 |
| Further information In July 2026, the licence for EURneffy was extended to include the 1mg nasal spray for the emergency treatment of severe allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise-induced anaphylaxis. Treatment is indicated for children aged 4 years and over weighing 15 kg to less than 30 kg. Health boards in Wales should also make this product available for prescribing in accordance with the AWMSG policy statement on paediatric licence extensions. |
|